Home  /  Resource Library  /  Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Results of a study investigating Pirtobrutinib for treatment of relapsed chronic lymphocytic leukemia and mantle cell lymphoma. (Abstract only)